VBI Vaccines to Host Hepatitis B Key Opinion Leader Meeting

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VBI Vaccines to Host Hepatitis B Key Opinion Leader Meeting

CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 10, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") will host a hepatitis B ("HBV") Key Opinion Leader meeting on Monday, June 13 at 12:00 PM ET. The event is being held at the Lotte New York Palace in New York City.

The event will feature keynote presentations by Dr. Daniel Shouval, M.D. and Dr. Florian Schödel, M.D., who will discuss new approaches to vaccination against hepatitis B as well as the unmet medical need. In addition, members of the VBI management team will provide an overview of Sci-B-Vac™ , a third-generation HBV vaccine that mimics all three viral surface antigens of the hepatitis B virus. Sci-B-Vac is approved in Israel and in 14 other countries and has demonstrated a favorable safety and efficacy profile in over 300,000 patients.

At the time of the event, a live webcast will be available at: http://lifesci.rampard.com/20160613/reg.jsp

Dr. Shouval is a Professor of Medicine and the former Dean of the Faculty of Medicine at the Hebrew University and Hadassah Medical School in Jerusalem, where he established Israel's first liver unit in 1983. He is a visiting Professor at Albert Einstein College of Medicine and has held similar positions at Harvard Medical School, Massachusetts General Hospital, and the University of Paris. Dr. Shouval currently serves as a standing adviser to the European Viral Hepatitis Prevention Board and the World Health Organization ("WHO"), and has previously served as both President and Chairman of the Educational Committee of the European Association for the Study of the Liver ("EASL").

Dr. Schödel has more than 20 years of pharmaceutical, biotech industry, and academic experience leading teams in the development of vaccines and biologics. A physician and microbiologist by training, Dr. Schödel holds adjunct faculty appointments at the University of Munich and at the Biodesign Center of ASU. Dr. Schödel's research has focused on novel recombinant vaccines against diseases including hepatitis B, malaria, and typhoid. He has led the clinical teams responsible for several successful vaccine filings in the U.S., the European Union, and globally, including several pediatric combination vaccines.

The event is intended for institutional investors and sell-side analysts only. If you would like to attend, please contact Mac MacDonald at (212) 915-2567 or via e-mail at mac@lifesciadvisors.com .

Event Details

About VBI Vaccines Inc.

VBI Vaccines Inc. ("VBI") is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI's first marketed product is Sci-B-Vac™, a hepatitis B ("HBV") vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI's eVLP Platform technology allows for the development of enveloped ("e") virus-like particle ("VLP") vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus ("CMV") and glioblastoma multiforme ("GBM"). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

Cautionary Statement on Forward-looking Information

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, "forward-looking statements") that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements.

Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company's products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.

VBI cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and VBI has made assumptions and estimates based on or related to many of these factors.

Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company's current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

VBI Contact Perri Maduri Communications Executive Phone: (617) 830-3031 x124 Email: ir@vbivaccines.com VBI Investor Contact Nell Beattie Director, Corporate Development and Investor Relations Phone: (617) 830-3031 x128 Email: nbeattie@vbivaccines.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 21

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 20

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 84

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 226

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Dar Global Expands Jeddah Portfolio with $267M Project

Updated Category News Views 77

Dar Global's Big Jeddah Move: A $267M Bet Alright, let's dive into what Dar Global's been up to in Saudi Arabia. They've just announced a whopping SAR 1 billion development project in Jeddah, bringing an international luxury brand to the city with an exclusive co-branded residential concept. Now that's something to chew on for any investor eyeing the Middle East's real...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 12

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading

Top 5 Most Recently Viewed Articles

STREAM Foundation Joins Forces with Greenwood Project for Growth

Updated Category News Views 138

STREAM Foundation Announces Exciting Collaboration The STREAM Foundation is thrilled to announce its upcoming merger with the Greenwood Project, a nationally renowned nonprofit dedicated to enhancing career pathways for underrepresented students. This strategic merger will significantly expand the breadth of resources and opportunities available to students interested in...

Continue Reading
Exploring the Future of Hydrogen Detection Technology and Growth

Updated Category News Views 545

Hydrogen Detection Market Size & Growth Insights The hydrogen detection market is on a remarkable trajectory, aiming to reach an impressive USD 642.39 million by 2032. This growth represents a substantial compound annual growth rate (CAGR) of 11.89% from 2024 to 2032, starting with a market valuation of USD 234.9 million in 2023. The ongoing emphasis on hydrogen as a...

Continue Reading
Ascletis Showcases Bold Moves in Obesity Drug Arena

Updated Category News Views 264

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...

Continue Reading
Top Precious Metal Stocks Impress Investors Amid Gold Surge

Updated Category News Views 326

Introduction to Precious Metals Stocks October has proven to be a prosperous month for precious metals stocks as they ascend into the upper echelons of market momentum rankings. This surge is primarily attributed to increased global demand, which is simultaneously boosting gold prices and favoring the miners’ positions. Gold's Resurgence Fuels Stock Momentum The recent...

Continue Reading
XTI Aerospace's Strategic Advancements and Financial Highlights

Updated Category News Views 156

XTI Aerospace's Significant Progress in Q3 2025 XTI Aerospace, Inc. (NASDAQ: XTIA) has made remarkable strides as a leader in vertical flight technologies. The company's innovative TriFan 600 aircraft is set to revolutionize commercial and defense aerospace applications. Recently, XTI announced its impressive achievements for the third quarter of 2025, marking a period...

Continue Reading